- Home
- CNSP vs ADXN Comparison
CNSP vs ADXN Comparison
Compare CNSP & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNSP | ADXN |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 8.6M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CNSP | ADXN |
|---|---|---|
| Price | $4.75 | $5.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 13.3K | 4.0K |
| Earning Date | 05-15-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $5.41 |
| 52 Week High | $10.59 | $12.05 |
Technical Indicators
Market Signals| Indicator | CNSP | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 40.67 |
| Support Level | $4.50 | $5.75 |
| Resistance Level | $5.61 | $7.37 |
| Average True Range (ATR) | 0.33 | 0.54 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 97.50 | 12.24 |
Price Performance
Historical ComparisonAbout CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.